Mark Stuart Anderson
Impact in
- Immunology top 0.1%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Infectious Diseases top 0.2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Immunology 100
- T-cell and B-cell Immunology 73
- Immune Cell Function and Interaction 57
- Immunotherapy and Immune Responses 21
- Immunodeficiency and Autoimmune Disorders 14
-
- Adrenal Hormones and Disorders 45
- Co-authors
- Jeffrey A. Bluestone (12 shared papers)Christophe O. Benoist (4 shared papers)Diane Mathis (4 shared papers)Maureen A. Su (17 shared papers)Emily S. Venanzi (2 shared papers)Stuart P. Berzins (2 shared papers)Zhibin Chen (2 shared papers)Roderick Terry Bronson (2 shared papers)
- Journals
- The Journal of Experimental Medicine (18 papers)Proceedings of the National Academy of Sciences (10 papers)Journal of Clinical Investigation (10 papers)The Journal of Immunology (8 papers)Nature (8 papers)
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Mark Stuart Anderson
219 papers receiving 21.3k citations
Mark Stuart Anderson's Hit Papers
Peers
Comparison fields: 5 of 158
- Immunology 9.3k
- Infectious Diseases 4.1k
- Endocrinology, Diabetes and Metabolism 3.6k
- Genetics 4.5k
- Neurology 2.1k
Countries citing papers authored by Mark Stuart Anderson
This map shows the geographic impact of Mark Stuart Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Stuart Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Stuart Anderson more than expected).
Fields of papers citing papers by Mark Stuart Anderson
This network shows the impact of papers produced by Mark Stuart Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Stuart Anderson. The network helps show where Mark Stuart Anderson may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Stuart Anderson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Hit paper breakdown → | 2020 | 2063 |
| 2 | Projection of an Immunological Self Shadow Within the Thymus by the Aire Protein Hit paper breakdown → | 2002 | 1989 |
| 3 | Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Hit paper breakdown → | 2020 | 1718 |
| 4 | THE NOD MOUSE: A Model of Immune Dysregulation Hit paper breakdown → | 2004 | 924 |
| 5 | Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM Hit paper breakdown → | 2022 | 622 |
| 6 | 2005 | 518 | |
| 7 | Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors Hit paper breakdown → | 2018 | 482 |
| 8 | Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths Hit paper breakdown → | 2021 | 466 |
| 9 | 2008 | 450 | |
| 10 | Detection of Succinate by Intestinal Tuft Cells Triggers a Type 2 Innate Immune Circuit Hit paper breakdown → | 2018 | 432 |
| 11 | 2008 | 394 | |
| 12 | Autoimmune Polyendocrine Syndromes Hit paper breakdown → | 2018 | 307 |
| 13 | 2015 | 292 | |
| 14 | Human genetic and immunological determinants of critical COVID-19 pneumonia Hit paper breakdown → | 2022 | 275 |
| 15 | Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes Hit paper breakdown → | 2019 | 269 |
| 16 | 2006 | 233 | |
| 17 | Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1 Hit paper breakdown → | 2021 | 232 |
| 18 | 2018 | 229 | |
| 19 | 2020 | 226 | |
| 20 | 2017 | 217 |
About Mark Stuart Anderson
Mark Stuart Anderson is a scholar working on Immunology, Endocrinology, Diabetes and Metabolism, Genetics, Infectious Diseases and Oncology, having authored 223 papers that have together received 21.7k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (73 papers), Diabetes and associated disorders (57 papers), Immune Cell Function and Interaction (57 papers), Adrenal Hormones and Disorders (45 papers), Immunotherapy and Immune Responses (21 papers), SARS-CoV-2 and COVID-19 Research (15 papers), Immunodeficiency and Autoimmune Disorders (14 papers) and Pancreatic function and diabetes (11 papers). The work is most often cited by research in Immunology (9.3k citations), Infectious Diseases (4.1k citations), Endocrinology, Diabetes and Metabolism (3.6k citations), Genetics (4.5k citations) and Neurology (2.1k citations). Mark Stuart Anderson has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Jeffrey A. Bluestone, Christophe O. Benoist, Diane Mathis, Maureen A. Su, Emily S. Venanzi, Stuart P. Berzins, Zhibin Chen, Roderick Terry Bronson, Shannon J. Turley and Ludger Klein. Their work appears in journals such as The Journal of Experimental Medicine, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation, The Journal of Immunology and Nature.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.